Back to DermorphinSecondary reference

Opioid peptide · Dermorphin

Dermorphin claimed effects and research context

What dermorphin is, why it is studied as an extremely potent opioid peptide, and why its notoriety comes from illicit misuse rather than any approved therapeutic benefit.

Educational only
This page is educational and not medical advice. See the medical disclaimer and editorial policy.

Quick facts

Family
Neuro / nootropic / cosmetic
About
Potent opioid-like peptide originally isolated from amphibian skin, occasionally discussed in experimental analgesia and performance contexts.
Important context

Dermorphin is a potent mu-opioid peptide with high abuse potential. It is not an approved therapeutic and is best understood through the lens of opioid pharmacology and its history of illicit misuse, not as a wellness or performance compound.

Overview

Dermorphin is a heptapeptide originally isolated from the skin of certain South American frogs. It draws scientific interest almost entirely because of its extreme potency as an opioid agonist. Any framing of "benefits" should be read narrowly as research interest, not as evidence of safe or approved use in people.

Mechanism and potency

Dermorphin binds with high selectivity to the mu-opioid receptor, the same receptor family targeted by morphine and related analgesics. Reports describe it as far more potent than morphine on a weight basis. That potency is exactly what makes it dangerous: it magnifies the classic opioid risks of sedation, respiratory depression, dependence, and overdose.

Research context

In the laboratory, dermorphin and related frog-skin peptides have been used as tools to study opioid receptor pharmacology and analgesia. Interest centers on:

  • Understanding mu-opioid receptor selectivity and signaling.
  • The unusual presence of a D-amino acid in a naturally occurring peptide.
  • Comparisons with other endogenous and exogenous opioids.

This is basic-science interest, not a demonstrated clinical role.

Misuse and the doping context

Dermorphin is best known publicly as a "frog juice" doping agent in horse racing, where it has been used illicitly to affect pain perception or performance in racehorses. This misuse is a warning sign, not a benefit: it reflects a powerful, hard-to-detect opioid being abused outside any legitimate medical framework.

Status and caveats

Key points to keep in mind:

  • Dermorphin is not FDA-approved for any use in humans.
  • As a potent opioid, it carries serious risks of respiratory depression, dependence, and overdose.
  • Its reputation derives from illicit doping, not from established therapy.

Sport & Anti-Doping Warning

Dermorphin became notorious in horse racing as a potent opioid peptide (sometimes dubbed 'frog juice') illegally administered to racehorses to dull pain and enhance performance.

Advisory Note

While most famous in veterinary sport, dermorphin and similar non-approved opioids would also be treated as prohibited narcotics in human athletics.

Keep reading

More on Dermorphin

Key studies

Curated primary literature for Dermorphin. Links open the publisher or PubMed record in a new tab.

  1. Amino acid composition and sequence of dermorphin, a novel opiate-like peptide from the skin of Phyllomedusa sauvageiPubMed
  2. In vitro and in vivo opioid activity of [DPro(6)]dermorphin, a new dermorphin analoguePubMed

Search the literature

PubMed · ClinicalTrials.gov · Google Scholar